UPDATE: Pivotal Research Group Initiates Coverage On Nu Skin Enterprises On Positive Outlook

In a report published Monday, Pivotal Research Group analyst Timothy S. Ramey initiated coverage on Nu Skin Enterprises (NYSE: NUS) with a Buy rating and $75.00 price target.In the report, Pivotal Research Group noted, "Nu Skin Enterprises is a Global Multi-Level Marketer (MLM) of skin care, nutritional supplements, and weight loss products. After five years of 20% CAGR in sales and 42% CAGR in EPS, Nu Skin hit turbulence in 2014 with a relatively short-lived three month regulatory investigation in China. While this has been successfully resolved, it created a stall in the Chinese business, and a huge negative comp for the 2nd half of 2014. We see EPS down 50% in the 2H and down 31% for the year. That's the bad news. The good news is that this is a short-term setback, not a long-term problem, in our view. We see 18% EPS growth in 2015 and a return to the historic growth trajectory. The core business is solid and China should return to significant growth. China remains the fastest growing MLM market in the world.”Nu Skin Enterprises closed on Friday at $43.60.